Epigallocatechin Gallate (EGCG): A Comprehensive Reference
1. Identity: Names, Source, and Forms
1.1 Chemical and Botanical Identity
Epigallocatechin gallate (EGCG), also known as epigallocatechin-3-gallate, is the ester of epigallocatechin and gallic acid, and is a type of catechin. EGCG is the major polyphenol found in green tea (Camellia sinensis) and most of the potential health benefits of green tea are attributed to it. Its systematic chemical name is (−)-epigallocatechin-3-gallate, and it carries the designation cis-configuration at the C-2 and C-3 stereocentres of the flavan ring. Structurally, it possesses a trihydroxyphenol (galloyl) ester group at the 3-position that is largely responsible for its potent reactivity and biological activity.
Tea, derived from Camellia sinensis (family Theaceae), is one of the most consumed beverages worldwide. The three main types of tea are green, oolong, and black tea. Green tea is made by quickly processing fresh leaves to avoid fermentation; oolong tea is partially fermented, while black tea is fully fermented before drying. The minimal processing of green tea leaves is critical: its health benefits are largely attributed to its minimal processing, which preserves pharmacologically active compounds, particularly catechins, a key class of polyphenols, with EGCG being the most abundant and bioactive.
1.2 Catechin Profile of Green Tea
Of all the antioxidant compounds found in green tea, the major constituents are polyphenols, including phenolic acids and catechins. Catechins from green tea belong to the family of flavonoids that are powerful antioxidants and free iron scavengers. The four major catechins in green tea are (–)-epigallocatechin-3-gallate (EGCG), (–)-epigallocatechin, (–)-epicatechin gallate, and (–)-epicatechin, and EGCG is both the most abundant and most biologically active.
The purified green tea polyphenols (GrTP) contain more than 95% polyphenols when analyzed with high-performance liquid chromatography (HPLC). Pure GrTP extracts contain the following percentage composition of polyphenols: (−)-epicatechin (EC) 35%, (−)-epigallocatechin (EGC) 15%, (−)-epicatechin-gallate (ECG) 4%, and (−)-epigallocatechin-3-gallate (EGCG) 38–40%.
1.3 Natural Sources and Concentrations
EGCG concentrations are highest in the very young unopened leaf, known as a bud, or tip. Matcha, a finely ground powder of specially cultivated and shade-grown green tea leaves, represents one of the most concentrated dietary sources of EGCG. A 2018 systematic review suggests that a 240 ml serving of green tea may provide around 187 mg of EGCG; however, catechin levels may vary widely depending on the product and preparation.
1.4 Common Forms and Preparations
EGCG is available in several commercial and research forms:
- Green tea infusion: Brewed from dried Camellia sinensis leaves; EGCG content varies with leaf grade, water temperature, steeping time, and leaf-to-water ratio.
- Standardized green tea extract (GTE): Typically a dry powder or capsule standardized to a defined percentage of total catechins or EGCG specifically; some preparations such as Polyphenon E contain 64% EGCG.
- Isolated EGCG: High-purity (≥98%) isolated compound used in research and some supplements.
- Nanoencapsulated EGCG: Encapsulation of EGCG in nano-carriers has significantly improved its solubility, stability, and bioavailability and facilitated targeted tumor delivery. Various nanoparticle strategies, including polymeric nanoparticles, micelles, lipid-based nanocarriers, metal nanoparticles, and silica nanoparticles, are currently employed to enhance EGCG stability and pharmacological activity.
- Topical preparations: EGCG has diverse applications in dermatology, including the treatment of viral warts, psoriasis, lichen sclerosus, acne, vaginal dryness, alopecia, and UV-induced skin damage.
2. Traditional and Historical Use
2.1 Origins in Chinese Culture
According to a Chinese legend, tea was discovered around 4,000 years ago by Emperor Shen Nung. One day while he was boiling water, leaves from a nearby tea tree were blown into his pot by the wind. Intrigued by the aroma and flavor, he tasted it, leading to the accidental discovery of tea.
Traditional Chinese Medicine (TCM) practitioners prescribed green tea for a range of conditions, including headaches and fatigue (the stimulating properties of caffeine), digestive complaints such as bloating, nausea, and diarrhea (tannins and catechins have astringent and antimicrobial properties), respiratory issues including chest congestion and coughs (theophylline is a natural bronchodilator), fevers and heat-related conditions (green tea's "cooling" nature in TCM classification), and as a general detoxifying agent to clear internal "dampness."
In Chinese medicine, green tea is thought to be effective as a cooling agent for treating diseases characterized by having too much internal heat, inflammation for example.
2.2 Spread to Japan and East Asia
When tea arrived in Japan in the 8th century via Chinese Buddhist monks, it carried its medicinal reputation. The Zen monk Eisai (1141–1215) wrote Kissa Yojoki ("Drinking Tea for Health"), one of Japan's earliest texts on tea, which describes tea as "a miraculous medicine." Matcha green tea, a finely ground powder of specially grown and processed green tea leaves, has been celebrated for centuries in traditional Japanese tea ceremonies.
Green tea, long consumed across Southeast Asia, is highly esteemed for its medicinal properties and is often favored over conventional treatments in Eastern cultures. Beyond its ceremonial and cultural significance, green tea was historically valued in traditional medicine for its stimulant, diuretic, and digestive properties.
2.3 Traditional Preparations
The European Medicines Agency (EMA) has published a Community herbal monograph on green tea leaves, acknowledging the traditional use of the whole dried leaf and the herbal preparations including comminuted herbal substance and powdered herbal substance. Traditional preparations across Asian cultures ranged from simple hot water infusions of dried leaves, to powdered leaf preparations (matcha whisked in hot water), to cold-water preparations. The concentration of EGCG in any given preparation is determined by whether the leaf is minimally processed (as in green tea) versus fully fermented (as in black tea), where oxidation substantially degrades catechin content.
3. Key Constituents and Active Compounds
3.1 Chemical Structure and Key Features
EGCG is the ester of epigallocatechin and gallic acid. It is the most abundant catechin in tea, a polyphenol with a defined chemical structure. Its polyphenolic scaffold consists of: a benzopyran (chroman) ring system (the A and C rings), a catechol-type B-ring (trihydroxyphenyl), and a galloyl ester group at the 3-position of the C-ring. This galloyl moiety contributes significantly to its antioxidant capacity and protein-binding affinity. EGCG has a molecular formula of C₂₂H₁₈O₁₁ and a molecular weight of approximately 458.37 g/mol.
3.2 Coexisting Bioactive Compounds in Green Tea
The active constituents of green tea are believed to be the polyphenols, commonly known as tea catechins. The major tea catechins are epigallocatechin gallate (EGCG), epigallocatechin (EGC), epicatechin gallate (ECG), and epicatechin (EC). Of these, EGCG is the most abundant and possesses the most potent antioxidative activity. Additionally, green tea contains caffeine, L-theanine, gallic acid, and various other phenolic acids that may act synergistically with EGCG.
4. Mechanisms of Action
4.1 Antioxidant Activity
Favorable effects of EGCG have been initially attributed to its scavenging effects on free radicals, inhibition of ROS-generating mechanisms, and upregulation of antioxidant enzymes. EGCG is a compound with a complex molecular structure that plays a crucial role in free radical scavenging and anti-inflammatory processes. Its intricate structure allows it to neutralize reactive oxygen species (ROS) and modulate complex inflammatory responses with precision. EGCG's ability to interact with free radicals at multiple sites prevents oxidative cascade reactions and supports cellular homeostasis.
Biological actions of EGCG are concentration-dependent and under certain conditions EGCG may exert pro-oxidant activities, including generation of free radicals. Several lines of evidence have shown that EGCG can stimulate ROS generation leading to the activation of AMP-activated protein kinase (AMPK) by phosphorylation. Phosphorylated AMPK generated by EGCG's action can modulate some proteins involved in adipogenesis, lipogenesis, and lipolysis — the so-called "AMPK hypothesis."
4.2 Anti-Inflammatory Pathways
Reactive oxygen species (ROS), a primary culprit in oxidative stress, have been demonstrated to be reduced by EGCG. Furthermore, nuclear factor kappa-B (NF-κB), a pivotal signal molecule of inflammation progress, has been observed to be suppressed by EGCG. EGCG's anti-inflammatory mechanisms involve modulating cellular signaling pathways, including suppressing NF-κB activation, a critical inflammatory transcription factor. EGCG inhibits pro-inflammatory cytokine production, interrupting inflammatory cascade processes and promoting resolution of responses. It activates Nrf2, a regulator of antioxidant defense, triggering comprehensive cellular protection strategies.
EGCG suppresses inflammation in human coronary artery endothelial cells by inhibiting NF-κB, and inhibits enhanced expression of adhesion molecules such as VCAM-1 and ICAM-1.
4.3 Anti-Cancer Mechanisms
EGCG exerts its anticancer effects through various mechanisms, including the inhibition of cell proliferation, induction of apoptosis, suppression of metastasis, and modulation of signaling pathways such as epidermal growth factor receptor (EGFR), phosphoinositide 3-kinase/protein kinase B (PI3K/Akt), mitogen-activated protein kinase (MAPK), and nuclear factor kappa B (NF-κB).
EGCG enhances gap junctional communication between adjacent cells and thus protects cells from tumor development. In addition, the anti-tumor effects of EGCG are partially related to its wide anti-inflammatory and antioxidant effects, as EGCG may suppress chronic inflammatory processes resulting in cell transformation and hyperproliferation and initiation of carcinogenesis.
Anti-apoptotic protein B-cell lymphoma 2 (Bcl-2) is suppressed by EGCG through down-regulation of NF-κB, which can explain the apoptosis-inducing property of EGCG in its anti-cancer effect.
4.4 Metabolic and AMPK Signaling
EGCG has diverse molecular actions on AMPK, NF-κB, and the 67-kDa laminin receptor. The 67-kDa laminin receptor is a cell-surface receptor to which EGCG binds with high affinity, triggering downstream signaling that mediates several of its anti-cancer and anti-allergic effects. EGCG is involved in the regulation of a wide range of cellular signaling pathways through which it can exert its multiple biological activities, potentially useful for preventing, mitigating, or slowing the progression of chronic disorders.
4.5 Epigenetic Modulation
EGCG and other compounds extracted from green tea have been shown to suppress carcinogen-induced production of reactive oxygen species (ROS) and DNA damage, as well as alter cell signaling pathways. Some researchers found that EGCG can suppress cancer by inhibiting DNA methylation, through anti-proliferation and by inducing cancer cell apoptosis. The selected studies highlighted the biological and pharmacological potential of EGCG, particularly its preventive effects through mechanisms such as oxidative stress reduction, lipid metabolism regulation, and epigenetic modulation.
4.6 Sirtuin and Autophagy Pathways
Sirtuins 1 (Sirt1) is a histone deacetylase, the obligate substrate of which is NAD+. Evidence suggests that EGCG can enhance the activities of Sirt1 to induce autophagy to protect against inflammation.
4.7 Iron Chelation
EGCG possesses documented iron-chelating properties. In colorectal cancer cell studies, EGCG upregulated transferrin receptor (TfR) protein and downregulated Ferritin-H (FtH) protein, indicating that iron chelation activity occurred. A molecular docking study demonstrated that EGCG is able to strongly interact with the ferritin protein with a high binding affinity (−7.3 kcal/mol) via strong hydrogen bonds. This iron chelation has implications for both cancer biology and for potential interactions with dietary iron absorption.
5. Scientific Evidence by Health Area
5.1 Cardiovascular Health
Epidemiological studies suggest that the beneficial cardiovascular health effects of diets rich in green tea are, in part, mediated by their flavonoid content, with particular benefits provided by members of this family such as EGCG.
Blood Pressure: A double-blind, randomized controlled trial investigated the effects of EGCG on blood pressure and autonomic nervous system function in obese subjects (n=30), randomly allocated to receive 150 mg EGCG twice a day or placebo for 8 weeks. After 8-week EGCG treatment, systolic blood pressure (SBP), diastolic blood pressure (DBP), and mean arterial pressure (MAP) significantly decreased (P < 0.05 for all).
Lipid Profiles: Participants receiving green tea extract exhibited markedly reduced LDL-C and total cholesterol levels relative to placebo controls. Based on available data, the supplemental intake of 150–300 mg/day of EGCG for roughly 12 weeks may help normalize blood lipid and glucose levels in individuals who are obese. The influence of such supplementation on other metabolic parameters such as blood pressure, insulin resistance, and body measurements, however, has not been consistent across studies.
Inflammation Markers: In a 2024 meta-analysis of randomized controlled trials in people with metabolic syndrome and related disorders, green tea supplementation (green tea extract, green tea leaf powder, or EGCG) for 4 to 16 weeks significantly decreased blood TNF-α levels (−0.4293 pg/mL; 95% CI, −0.7821 to −0.0764; p=0.0171) but did not affect CRP and IL-6 levels.
Evidence Strength: EGCG has demonstrated pleiotropic bioactivity in preclinical models, encompassing potent antioxidant, anti-inflammatory, and anti-apoptotic properties. However, significant gaps must be addressed for clinical application. The body of human trial evidence for cardiovascular outcomes remains heterogeneous in dosing and duration, with promising but not definitive results.
5.2 Metabolic Syndrome, Obesity, and Body Weight
Many clinical studies have demonstrated that EGCG is associated with positive effects on various health parameters, including metabolic biomarkers, waist circumference, and body weight when consumed by individuals affected by obesity and NAFLD.
In a randomized, double-blind, placebo-controlled study, eighty-three obese (BMI 30–40 kg/m²) pre-menopausal women consumed 300 mg/day of EGCG or placebo alongside an energy-restricted diet intervention. Ongoing debate persists regarding the value of low-dose EGCG (150–300 mg/day) as a means of improving the metabolic status of obese individuals alone or in combination with exercise or other polyphenols. Additional long-term clinical studies will be vital to clarify how EGCG impacts obesity-associated metabolic parameters.
At dietary levels (approximately less than 300 mg/day from brewed green tea) EGCG is generally safe and associated with modest improvements in weight management, LDL oxidation, endothelial function, and markers of oxidative stress.
Evidence Strength: Short-term (4–16 week) randomized controlled trials show modest, statistically significant effects on select metabolic biomarkers; long-term data are limited and effects on body weight specifically are inconsistent.
5.3 Cancer Prevention and Oncology
EGCG, the major bioactive polyphenol in green tea, has garnered significant attention for its potential anticancer properties. Current evidence comes from in vitro, in vivo, and some clinical trials examining the effects of EGCG on various cancers.
EGCG exerts its anticancer effects through various mechanisms, including inhibition of cell proliferation, induction of apoptosis, suppression of metastasis, and modulation of signaling pathways such as EGFR, PI3K/Akt, MAPK, and NF-κB. Additionally, EGCG has been shown to enhance the efficacy of conventional chemotherapeutic agents and mitigate drug resistance. However, challenges related to its bioavailability and metabolic stability remain.
In animal studies, in an in vivo xenograft experiment on mice, EGCG treatment resulted in a 45.2% reduction in tumor size compared with the control group without weight loss. There were noteworthy differences in Ki-67 expression between the EGCG treatment group and control group, and the percentage of apoptotic cells in the EGCG treatment group was meaningfully larger than that in the control group.
Evidence Strength: Laboratory experiments have provided evidence that EGCG modulates numerous molecular targets and inhibits the pathogenesis of cancer through inhibition of initiation, promotion, and progression. Moreover, clinical human trial-based studies are still needed to establish the efficacy of EGCG in management of cancer. Most mechanistic evidence remains preclinical (in vitro and animal models). Human trial data are limited and preliminary.
5.4 Neurodegenerative Diseases and Neuroprotection
Chronic neuroinflammation is associated with many neurodegenerative diseases, such as Alzheimer's disease. Microglia are the brain's primary immune cells, and when activated, they release various proinflammatory cytokines. Several natural compounds with anti-inflammatory and antioxidant properties, such as EGCG, may provide a promising strategy for inflammation-related neurodegenerative diseases involving activated microglia cells.
EGCG targets inflammation and synaptic dysfunction in Alzheimer's disease by modulating microglial activation, reducing pro-inflammatory cytokines and promoting the release of anti-inflammatory factors. It enhances synaptic plasticity by promoting BDNF expression and protecting against Aβ-induced synaptic toxicity.
EGCG has been shown to promote non-amyloidogenic processing of amyloid precursor protein (APP) by upregulating α-secretase, thus preventing brain beta amyloid plaque formation, a hallmark of Alzheimer's pathology.
The translation into clinical use has been problematic primarily as a result of poor bioavailability and inefficient delivery to the central nervous system (CNS).
Evidence Strength: Predominantly preclinical (cell culture and animal models). Some human observational data are supportive, but well-powered randomized clinical trials in neurodegeneration are lacking. Evidence remains preliminary.
5.5 Type 2 Diabetes and Insulin Sensitivity
Cao et al. found that high-fat-diet-induced increases in inflammatory TNFα levels and infiltrating CD68+ macrophage counts in rat islets were attenuated by supplementation of EGCG, suggesting that EGCG's anti-diabetic effect may be mediated by suppressing inflammation, including suppression of NF-κB activity. EGCG has been shown to influence key physiological pathways, particularly those related to lipid metabolism and inflammation, offering protective effects against a variety of diseases. EGCG's ability to modulate cell signaling pathways associated with oxidative stress, apoptosis, and immune regulation highlights its multifaceted role in health promotion.
Evidence Strength: Mechanistic evidence is strong in vitro and in animal models. Human clinical trial evidence on glucose metabolism and insulin sensitivity is supportive but mixed; studies differ substantially in dose, duration, and population.
5.6 Skin and Dermatological Applications
EGCG and related catechins exhibit antioxidant, anti-cancer, antimicrobial, and antiangiogenic properties. EGCG has diverse applications in dermatology, including the treatment of viral warts, psoriasis, lichen sclerosus, acne, vaginal dryness, alopecia, and UV-induced skin damage. Emerging research also highlights its promise in aesthetic medicine for mitigating skin oxidative stress, improving skin brightness and neutralizing free radicals, responsible for wrinkles, hyperpigmentation, and loss of elasticity.
Evidence Strength: Early-stage clinical evidence exists for specific dermatological conditions (particularly topical use for viral warts). For cosmetic applications, evidence is mostly preliminary and often based on in vitro or small clinical studies.
5.7 Cardio-Oncology
This area of research addresses the critical overlap of heart failure and cancer pathologies, which share fundamental drivers such as oxidative stress, inflammation, and metabolic dysregulation. EGCG has demonstrated pleiotropic bioactivity in preclinical models, encompassing potent antioxidant, anti-inflammatory, and anti-apoptotic properties. EGCG is positioned not merely as a nutraceutical, but as a multi-target molecular therapeutic capable of simultaneously addressing the convergent pathological cascades of heart failure and cancer-related cardiotoxicity.
Evidence Strength: Preclinical only at present. Human trials are needed to validate these observations.
6. Bioavailability and Pharmacokinetics
EGCG, a major polyphenolic compound in tea leaves, exhibits potent antioxidant, anti-inflammatory, and anticancer properties. Despite its therapeutic potential, poor bioavailability limits clinical efficacy.
EGCG reaches peak plasma concentration within 1–4 hours after consumption, then declines with a half-life of approximately 3.9 hours. Oral bioavailability of EGCG is limited by: chemical instability at alkaline pH and elevated temperatures, extensive first-pass metabolism and conjugation in the gut wall and liver, and protein binding in the gastrointestinal tract.
Another limiting factor is EGCG's low bioavailability after oral administration. To address this challenge, nanoparticles, with their unique physicochemical properties, offer a platform for the enhanced stability, bioavailability, and targeted delivery of EGCG. Various nanoparticle strategies, including polymeric nanoparticles, micelles, lipid-based nanocarriers, metal nanoparticles, and silica nanoparticles, are currently employed to enhance EGCG stability and pharmacological activity. EGCG nanoparticles can significantly modify the pharmacokinetic profile and increase the bioavailability of EGCG by more than 2.4-fold in comparison with the EGCG powder group.
The particle sizes of most formulated nanocarriers fall within 300 nm and their encapsulation efficiency ranges from 51% to 97%. Notably, the pharmacological activities of EGCG-loaded nanoparticles, such as antioxidative, anti-inflammatory, anticancer, and antimicrobial effects, are significantly enhanced compared to those of free EGCG.
7. Dosage Forms and Reported Doses
Dosage varies substantially across studies. The following dosages are those reported specifically in the cited sources:
- A 2018 systematic review suggests that a 240 ml serving of green tea may provide around 187 mg of EGCG.
- In a double-blind, randomized controlled trial in obese subjects (n=30), participants received 150 mg EGCG twice a day (300 mg/day total) for 8 weeks.
- In a randomized, double-blind, placebo-controlled study in obese women (n=83), 300 mg/day of EGCG was administered.
- Based on available clinical data, supplemental intake of 150–300 mg/day of EGCG for roughly 12 weeks appears relevant to lipid and glucose normalization in obese individuals.
- A systematic review based on 4 randomized controlled trials examined relatively high doses of green tea extracts containing 800–1600 mg of EGCG or 500 mg of green tea polyphenol.
- Reported EGCG content in catechin extracts used in clinical research ranged from 56–72% in Polyphenon E (a decaffeinated extract of green tea containing 64% EGCG) to pure EGCG.
- One 2019 article suggests EGCG may be safe in doses as high as 3 grams (g) per day.
- Strategies to enhance bioavailability such as nanotechnology, chemical modification, and combination drug regimens are being explored; based on existing human clinical trials, recommendations for effective and safe dosage ranges of EGCG intake are provided in dedicated reviews.
8. Safety Considerations and Drug Interactions
8.1 General Safety Profile at Dietary Levels
The EFSA Panel concluded that catechins from green tea infusion, prepared in a traditional way, and reconstituted drinks with an equivalent composition to traditional green tea infusions, are in general considered to be safe according to the presumption of safety approach, provided the intake corresponds to reported intakes in European Member States.
In Cochrane meta-analyses of clinical trials in healthy adults and those at high risk of cardiovascular disease (totaling 821 subjects), side effects were mild and no significant differences in adverse events were observed between green tea and placebo groups.
8.2 Hepatotoxicity — the Central Safety Concern
For food supplements, EFSA's experts concluded — on the basis of human studies conducted with volunteers under medical supervision — that doses of EGCG at 800 mg/day may be associated with initial signs of liver damage. For green tea infusions, EFSA's experts concluded that there is generally no indication of liver damage even after high consumption, and that the few cases of liver damage reported in humans are likely due to rare and unpredictable reactions.
The EFSA Panel evaluated a total of 49 intervention studies on green tea preparations. No intervention studies in pregnant women, breastfeeding infants, or children were identified. Following review of the 49 studies, 9 studies reported elevated liver transaminases. However, two of the studies considered did not include a control group and were thus excluded. In the 7 remaining studies showing a higher incidence of abnormal liver parameters, doses of EGCG were 800 mg or above.
There are uncertainties around the mechanism(s) leading to both the dose-dependent hepatotoxicity of EGCG and the mechanism(s) leading to idiosyncratic hepatotoxicity to EGCG.
Concentrated extracts (≥800 mg/day) increase systemic exposure but carry a rare risk of idiosyncratic hepatotoxicity.
EGCG caused dose-dependent hepatotoxicity in mice under dietary restriction, suggesting potential combination effects of dietary restriction and EGCG. The combination effect led to overactivation of linoleic acid and arachidonic acid oxidation pathways, significantly increasing the accumulation of pro-inflammatory lipid metabolites and thus mediating liver injury.
Some concerns persist that use of EGCG at high doses may lead to hepatotoxicity, particularly at doses exceeding 400 mg/day.
8.3 EU Regulatory Response
Based on EFSA's opinion, the European Commission amended Annex III of Regulation (EC) No 1925/2006 to establish new limits for EGCG in foods. The legislation suggests a daily intake level of EGCG from green tea extracts at 800 mg/day, but recommends studies be conducted to determine a dose-response of hepatotoxicity of green tea catechins and examine inter- and intra-species variability. The compound will be further reviewed within the EU. According to the new rules, a daily serving of green tea extract in foods and supplements must contain less than 800 mg of EGCG, and the label must state that the total daily amount of 800 mg must not be exceeded.
8.4 Fasted vs. Fed State Administration
Fasted animal subjects showed mild liver damage, whereas no changes were observed in the livers of fed animals. Exposure to EGCG (in terms of AUC and Cmax) was considerably lower in fed subjects than in fasted ones, which might explain, at least in part, the difference in toxicity in the fasted state. Although the evidence is inconclusive, studies suggest that green tea extract be taken with food to minimize the risk of liver damage.
8.5 Iron Absorption Interference
EGCG's documented iron-chelating capacity has practical implications for nutritional status. Caffeine in green tea can cause mild to severe adverse reactions including headache, insomnia, tremor, convulsions and confusion, and may interfere with iron absorption. EGCG itself binds non-heme iron in the gastrointestinal lumen, potentially reducing its absorption, which is particularly relevant in populations at risk for iron deficiency.
8.6 Drug Interactions
Green tea polyphenols interfere with many drugs. The most important of these polyphenol compounds is EGCG, and most of the reported interactions are due to its presence. Interactions with different drugs occur in the context of both pharmacodynamics and pharmacokinetics, including drug absorption, metabolism, and renal excretion.
Specific interactions documented in the research literature include:
- Research in rats showed that co-administration of green tea with digoxin increased the Cmax of digoxin, potentially due to enhanced absorption.
- Administration of green tea extract with erlotinib or lapatinib resulted in a significant decrease in the AUC and Cmax of both drugs, an interaction probably due to P-glycoprotein inhibition by EGCG.
- EGCG can inhibit UDP-glucuronosyltransferases (UGTs), enzymes involved in drug metabolism.
- Moderate interactions could occur with adenosine, oral contraceptives, antibiotics, antidepressants (MAOIs), anticoagulants and antiplatelet drugs, clozapine, lithium, theophylline, verapamil, and any hepatotoxic drugs.
8.7 Contraindications
Contraindications cited in regulatory literature include hypersensitivity to the active substance(s), gastric and duodenal ulcers, cardiovascular disorders such as hypertension and arrhythmia, and hyperthyroidism.
8.8 Labeling Considerations
EFSA said it was unable to determine a "safe level" for catechins in supplements, but noted that green tea products — and in particular supplements — should include the content of catechins and the proportion of EGCG on labels.
8.9 Genetics and Individual Susceptibility
As EGCG sensitivity may also be influenced by individual genetics, additional research should explore the role of genetic variability in EGCG-related hepatotoxicity. Research cited in systematic reviews has examined catechol-O-methyltransferase (COMT) and UGT1A4 genotypes as potential modifiers of hepatotoxic risk at high doses.
9. Body Systems Associated with EGCG Research
EGCG plays a key role in regulating cell signaling pathways associated with various chronic conditions, including cardiovascular diseases, neurodegenerative disorders, metabolic diseases, and cancer. Based on the research literature, the following body systems have been investigated:
- Cardiovascular system: Blood pressure regulation, LDL oxidation, endothelial function, atherosclerosis prevention.
- Metabolic/endocrine system: Adipogenesis, insulin sensitivity, lipid metabolism, non-alcoholic fatty liver disease.
- Nervous system: Neuroprotection in Alzheimer's disease and Huntington's disease; reduction of neuroinflammation via microglial modulation.
- Immune system: Modulation of pro-inflammatory cytokines (TNF-α, IL-6), suppression of NF-κB and mTOR pathways.
- Integumentary (skin) system: Anti-aging, UV protection, acne, psoriasis, alopecia.
- Oncology (multiple systems): Inhibition of cancer cell proliferation and induction of apoptosis across lung, prostate, breast, colorectal, and oral cavity cancer cell lines.
- Gastrointestinal system: Gut microbiota modulation, antimicrobial effects.
A 2025 comprehensive review examined the multifunctional bioactivities of EGCG, including its antioxidant, anti-inflammatory, anticancer, cardiovascular protective, metabolic regulatory, neuroprotective, gut microbiota-modulating, and antimicrobial properties.
10. Evidence Summary and Limitations
A systematic literature survey identified 17 relevant clinical studies classified into five key areas related to catechin interventions: toxicity and detoxification, drug pharmacokinetics, cognitive functions, anti-inflammatory and antioxidant properties, and obesity and metabolism. Findings from these clinical studies suggest that the health benefits of green tea catechins outweigh the potential risks.
However, the overall body of clinical evidence for EGCG must be interpreted with important caveats. Challenges related to its bioavailability and metabolic stability remain. Many mechanistic studies are in vitro or animal-based, and dose translation to humans is uncertain. Human trials frequently differ in EGCG dose, formulation, duration, population characteristics, and outcome measures, making direct comparison difficult. Further exploration in both experimental and clinical settings is essential to fully unlock its therapeutic potential.
References
- Epigallocatechin-Gallate (EGCG): An Essential Molecule for Human Health and Well-Being — PMC (2025)
- Epigallocatechin Gallate (EGCG): Pharmacological Properties, Biological Activities and Therapeutic Potential — PMC (2025)
- Effects of Epigallocatechin Gallate Against Lung Cancer: Mechanisms of Action and Therapeutic Potential — PMC / Nutrients (2026)
- Epigallocatechin Gallate as a Molecular Therapeutic in Heart Failure and Cardio-Oncology — PMC (2025)
- Dietary (−)-Epigallocatechin Gallate (EGCG): State-of-the-Art Advances in Bioactivities, Bioavailability Enhancement Strategies, and Applications — PMC (2025)
- Catechins and Human Health: Breakthroughs from Clinical Trials — PMC (2025)
- The Safety and Efficacy of Dietary EGCG Supplementation for Obesity and NAFLD: Recent Updates — PMC (2025)
- Potential Therapeutic Targets of EGCG in Various Types of Cancer — PMC (2020)
- Therapeutic Effects of EGCG in Relation to Inflammation, Oxidative Stress, and Apoptosis — PMC (2022)
- Molecular Mechanisms of the Anti-Inflammatory Effects of EGCG in LPS-Activated BV-2 Microglia Cells — PMC (2023)
- Iron Chelation Properties of Green Tea EGCG in Colorectal Cancer Cells — PMC (2020)
- In Vitro and In Silico Studies of the Molecular Interactions of EGCG with Proteins — PMC (2018)
- Epigallocatechin Gallate: A Review of Its Beneficial Properties to Prevent Metabolic Syndrome — PMC (2015)
- Epigallocatechin Gallate During Dietary Restriction — Potential Mechanisms of Enhanced Liver Injury — PMC (2021)
- Enhanced Oral Bioavailability of EGCG Using pH-Sensitive Polymeric Nanoparticles — PMC (2018)
- Nanolipidic Particles Improve the Bioavailability and Alpha-Secretase Inducing Ability of EGCG for Alzheimer's Disease — PMC (2018)
- Epigallocatechin-3-gallate at the nanoscale: a new strategy for cancer treatment — PMC (2024)
- EGCG as a therapeutic agent: a systematic review of recent advances and challenges in nanocarrier strategies — PMC (2025)
- EFSA assesses safety of green tea catechins — EFSA (2018)
- Scientific opinion on the safety of green tea catechins — EFSA Journal (2018)
- Statement on the Hepatotoxicity of Green Tea Catechins — UK Committee on Toxicity
- The effects of green tea supplementation on cardiovascular risk factors: A systematic review and meta-analysis — Frontiers in Nutrition (2022)
- Epigallocatechin gallate enhances sympathetic heart rate variability and decreases blood pressure in obese subjects: a randomized control trial — Scientific Reports (2024)
- Effects of dietary supplementation with EGCG on weight loss, energy homeostasis, cardiometabolic risk factors and liver function in obese women — PubMed (2014)
- Epigallocatechin-3-Gallate (EGCG): Mechanisms, Perspectives and Clinical Applications in Cervical Cancer — MedCrave (2018)
- The Intrinsic Virtues of EGCG on Prevention and Treatment of Diabesity Complications — PMC (2020)
- Neuroprotective insights into epigallocatechin gallate (EGCG) for neurodegenerative disorders — Exploration Neuroscience (2025)
- Bioinformatic Prediction of Possible Targets of EGCG Against Breast Cancer — PMC (2017)
- Epigallocatechin Gallate (EGCG) — Cognitive Vitality for Researchers, Alzheimer's Drug Discovery Foundation
- Drug Interactions of Green Tea — ResearchGate / peer-reviewed review
- Green Tea — Journal of Primary Health Care (2016)
- EU Limits Green Tea Extract with EGCG in Foods — Food Safety Magazine (2022)
- Targeting aging pathways with natural compounds: curcumin, EGCG, thymoquinone, and resveratrol — Immunity & Ageing / Springer (2025)
Go back